This page is a quick-access route for patients, healthcare professionals and distributors to report suspected adverse drug reactions (ADRs) related to DEFRATAJ Deferasirox. For the full pharmacovigilance policy, see Pharmacovigilance.
Quick Reporting Channels #
Post
Qualified Person for Pharmacovigilance
Taj Pharmaceuticals Limited
Mumbai, Maharashtra, India
What to Report #
- Any suspected adverse reaction - known or unexpected
- Lack of efficacy
- Drug interactions
- Medication errors or overdose
- Use during pregnancy or breast-feeding
- Suspected severe cutaneous reactions (SJS, TEN, DRESS)
- Product-quality complaints (appearance, packaging integrity)
Minimum Information Needed #
- An identifiable reporter (name, role, contact)
- An identifiable patient (initials, age or age-group, sex)
- A suspect product (DEFRATAJ, strength, batch, dates of use)
- A suspected adverse reaction (description, onset, current status)
Additional details (medical history, concomitant medicines, investigations, treatment) materially improve case assessment.
Local Authority Reporting #
Please also report to your national pharmacovigilance authority - India PvPI, Brazil ANVISA, USA FDA MedWatch, EU Yellow Card or equivalent in your country.
Confidentiality #
All reports handled confidentially per our Privacy Policy and international pharmacovigilance standards.
For Distributors #
Distributors should follow the signed Pharmacovigilance Agreement for case-forwarding timelines. Serious cases: forward to Taj Pharma within 24 hours of awareness.